Bacterium Or Component Thereof Or Substance Produced By Said Bacterium (e.g., Legionella, Borrelia, Anaplasma, Shigella, Etc.) Patents (Class 424/234.1)
  • Patent number: 11066638
    Abstract: The present invention relates to bacterial ghosts, and more particularly, to a method of preparing bacterial ghosts from gram-positive bacteria by hydrochloric acid treatment. Specifically, according to the present invention, when gram-positive bacteria were cultured after being treated with a minimum inhibitory concentration (MIC) of hydrochloric acid capable of inhibiting colony formation of gram-positive bacteria, bacterial ghosts were effectively formed. Since the formed bacterial ghosts have no intracellular proteins or DNA while preserving cell wall integrity, the risk of side effects such as secondary infection caused by bacterial growth when the bacterial ghosts are administered to humans is low. Therefore, the bacterial ghosts prepared from gram-positive bacteria according to the method of the present invention may be effectively used as a vaccine or a foreign antigen carrier for preventing or treating gram-positive bacterial infection.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: July 20, 2021
    Assignee: PAICHAI UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Chang Won Choi, Seong Mi Ji, Hyun Jung Park, Sung Oh, Nagarajan Vinod, Han Byul No
  • Patent number: 11052142
    Abstract: For the first time individual (free from impurities of penta- and hexa-acetylated derivatives) di-, tri- and tetra-acetylated S-LPS of endotoxic bacteria and combinations thereof were obtained and their immunobiological, physical-chemical and chemical-pharmaceutical properties were studied. For the first time the principal possibility of their clinical application was directly demonstrated as vaccines and pharmaceutical compositions containing the modified S-LPS individual as monocomponent or combinations thereof as two and three component active substance, respectively. The modified S-LPS and combinations thereof have high safety profile and provide low pyrogenicity and high immunogenicity. Developed on their basis vaccines and pharmaceutical compositions demonstrate anti-shock activity, high efficiency and specificity, broad-spectrum action and also good chemical-pharmaceutical parameters.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: July 6, 2021
    Inventors: Petr Gennadievich Aparin, Vyacheslav Leonidovich Lvov, Stanislava Ivanovna Elkina, Marina Eduardovna Golovina
  • Patent number: 10925906
    Abstract: An object of the present invention is to provide a brain function improving agent for neonates, especially, newborn neonates. According to the present invention, there is provided a brain function improving agent for neonates, comprising a lactic acid bacterium and/or a Bifidobacterium. The brain function improving agent or composition for improving brain function for neonates according to the present invention is advantageous in that the use thereof can improve the developmental quotient without any side effect and also enables effective development and growth of neonates.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: February 23, 2021
    Inventors: Satoshi Kusuda, Satsuki Totsu, Masaki Terahara
  • Patent number: 10914739
    Abstract: Mycobacterial-specific biomarkers and methods of using such biomarkers for diagnosis of mycobacterial infection in a mammal are disclosed.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: February 9, 2021
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventor: Adel M. Talaat
  • Patent number: 10905748
    Abstract: A composition and method of maintaining fertility or treating retained placenta, reproductive tract infection, or reproductive tract inflammation in an animal involves administering ovotransferrin to the reproductive tract of the animal. The ovotransferrin administration protects against and treats reproductive tract infection, while protecting against and treating reproductive tract inflammation such as metritis, and thereby maintains fertility in the animal.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: February 2, 2021
    Assignee: VETS PLUS, INC.
    Inventors: Jamil Talukder, Abhijit Ray, Daniel J. DuBourdieu, Ajay Srivastava, Rajiv Lall
  • Patent number: 10883988
    Abstract: Definitive diagnosis and early start of treatment cannot be made for tuberculosis since conventional methods for detecting a Mycobacterium tuberculosis complex require a long time plus enormous labor and expense. Because detection is difficult to perform directly from a biological sample, if the biological sample contains no or a very small amount of the Mycobacterium tuberculosis complex-specific secretory protein, there is a risk infection with the Mycobacterium tuberculosis complex will be missed.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: January 5, 2021
    Assignee: TAUNS CO., LTD.
    Inventors: Urao Nonaka, Toshiyuki Kitagawa
  • Patent number: 10858670
    Abstract: The present invention relates to vesicles derived from genus Morganella bacteria and a use thereof, the present inventors experimentally confirmed that the vesicles were significantly decreased in clinical samples derived from patients with a malignant disease such as gastric cancer, colorectal cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer and lymphoma, a cardiovascular disease such as myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, and stroke, diabetes mellitus, and Parkinson's disease as compared to normal persons, and the vesicles suppressed the secretion of inflammatory mediators by pathogenic vesicles and suppressed the occurrence of cancer, so that the vesicles derived from genus Morganella bacteria may be usefully used for the purpose of developing a method for diagnosing a malignant disease such as gastric cancer, colorectal cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cance
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: December 8, 2020
    Assignee: MD HEALTHCARE INC.
    Inventor: Yoon-Keun Kim
  • Patent number: 10858700
    Abstract: The present disclosure provides methods and reagents for improving nanopore-based analyses of polymers. Specifically, the disclosure provides a method of analyzing a polymer that includes a polymer analyte that contains an end domain that has at least one charged moiety. The disclosure also provides a method of increasing the interaction rate between a polymer analyte and a nanopore, wherein the polymer analyte contains an end domain that has at least one charged moiety. The disclosure also provide compositions for use with the described methods, including adapter compositions that contain charged moieties, such as phosphate or sulfate groups, and that are configured to being linked to an polymer analyte domain.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: December 8, 2020
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Jens H. Gundlach, Andrew Laszlo
  • Patent number: 10782293
    Abstract: A method of determining whether an individual is infected with a mycobacterial disease, the method comprising: (a) providing a system which comprises an antigen; (b) contacting the system with a sample obtained from the individual; and (c) detecting the presence or absence of binding of a biomarker in the sample with the antigen; wherein the antigen is a mycolic acid wax ester derived antigen.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: September 22, 2020
    Assignee: DIAGNOSTIG LTD
    Inventors: Mark Stephen Baird, Christopher David Gwenin, Juma'a Raheem Najeem Al Dulayymi, Salam Ghafour Taher
  • Patent number: 10781237
    Abstract: Provided herein are mutant single-chain Mycobacterium smegmatis porin (Msp) and uses thereof.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: September 22, 2020
    Assignee: THE UAB RESEARCH FOUNDATION
    Inventors: Michael Niederweis, Mikhail Pavlenok
  • Patent number: 10772968
    Abstract: A water soluble polymer, in particular polysialic acid (PSA) or a modified PSA (mPSA), is conjugated to an oxidized carbohydrate moiety of a glycoprotein other than a blood coagulation protein or to a ganglioside or drug delivery system by contacting the oxidized carbohydrate moiety with the water soluble polymer, wherein said water soluble polymer contains an aminooxy group and an oxime linkage is formed between the oxidized carbohydrate moiety and the aminooxy group on the water soluble polymer or wherein said water soluble polymer contains a hydrazide group and a hydrazone linkage is formed between the oxidized carbohydrate moiety and the hydrazide group on the water soluble polymer. Conjugates of aminooxy- or hydrazide-water soluble polymer, such as PSA and mPSA, are thus obtained in which the PSA or mPSA is attached via a carbohydrate moiety.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: September 15, 2020
    Assignees: Lipoxen Technologies Limited, Baxalta Incorporated, Baxalta GmbH
    Inventors: Sanjay Jain, Gregory Gregoriadis, Archana Dwivedi, Srijit Nath, Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
  • Patent number: 10765623
    Abstract: The present specification discloses a composition for preventing hair loss or promoting hair growth comprising, as an active ingredient, extracellular follicles derived from lactic acid bacteria, and a method for preparing the extracellular follicles derived from lactic acid bacteria. The composition has an effect of preventing and prohibiting hair from falling off from the scalp or becoming thin or tapered. In addition, the composition has an effect of implementing a hair growth function for generating new hair, or a function for promoting the hair growth, as well as a function of promoting a delay from an anagen to a catagen phase of a hair cycle and a function of growing the existing hair healthy.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: September 8, 2020
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Sung Tae Kim, Yonghee Lee, Seung Hyun Shin, Hyun Gee Lee, Eun-Gyung Cho, Tae Ryong Lee
  • Patent number: 10736959
    Abstract: The invention provides a process for preparing a conjugate of a S. aureus type 5 or type 8 capsular polysaccharide and a carrier molecule, comprising the steps of: (a) depolymerising the capsular polysaccharide, to give a polysaccharide fragment; (b) oxidising the fragment in order to introduce an aldehyde group into at least one saccharide residue in the fragment, to give an oxidised saccharide residue; and (c) coupling the oxidised saccharide residue to a carrier molecule via the aldehyde group, thereby giving the conjugate. The coupling in step (c) may be direct, or may be via a linker molecule. The invention also provides a conjugate obtained or obtainable by this process.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: August 11, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Francesco Berti, Paolo Costantino, Maria Rosaria Romano
  • Patent number: 10718766
    Abstract: The disclosure provides methods, compositions, and kits for enhanced detection of microbes in samples and monitoring of antimicrobial activity in a subject.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: July 21, 2020
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Mark J. Cartwright, Nazita Gamini, Donald E. Ingber, Martin Rottman, Michael Super, Julie A. Tomolonis, Karen A. Sinclair
  • Patent number: 10679725
    Abstract: The present invention relates to a combination of experimental and computational workflows that allow characterization of specific molecular mechanisms by which the microbiome contribute to skin health and skin age.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: June 9, 2020
    Assignee: PRODERMIQ, INC.
    Inventors: Dana Hosseini, Sasan Amini, Eveie Schwartz
  • Patent number: 10668136
    Abstract: The present invention relates to the treatment of autoimmune and allergic diseases by mucosal delivery by micro-organism, in particular Lactococcus lactis, of secreted immunodominant antigens.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: June 2, 2020
    Assignee: INTREXON ACTOBIOTICS NV
    Inventors: Pieter Rottiers, Veerle Snoeck
  • Patent number: 10646559
    Abstract: The present invention provides antigens, for use in the treatment or prevention of C. burnetii infection. Also provided are nucleic acids encoding such antigens, and antibodies raised against such antigens.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: May 12, 2020
    Assignee: SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE
    Inventors: Julia Vipond, Kevin Bewley
  • Patent number: 10548917
    Abstract: Embodiments of a method and supplement for preventing and/or treating gastrointestinal distress, including ulcer conditions, in animals are disclosed. The supplement comprises mastic gum and an emulsifying agent such as lecithin. The supplement may also comprise B vitamins, one or more prebiotics or probiotics, and one or more minerals as well as, pH buffers and flavoring. A disclosed method of preventing and/or treating gastrointestinal distress comprises orally dosing an animal with the supplement at least one daily.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: February 4, 2020
    Assignee: KAECO Group Inc.
    Inventors: Kelly Terry, Leon Kratochvil, James Harless, Tom Kratochvil
  • Patent number: 10494684
    Abstract: A spore-forming Bacillus species, and more particularly, a Bacillus subtilis strain identified as MB40 is provided. Compositions comprising the MB40 strain, methods of making products comprising the same, and methods of using the same are also provided.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: December 3, 2019
    Assignee: BIO-CAT, INC.
    Inventors: Christopher S. Penet, Sebhat Gebrechristos, Caroline Helen Best, Deborah S. Winetzky, Robert Daniel Little, Jr., Jessica Spears, Christopher Schuler
  • Patent number: 10441645
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Mesothelin. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: October 15, 2019
    Assignee: VAXIMM GMBH
    Inventors: Marco Springer, Heinz Lubenau
  • Patent number: 10406184
    Abstract: Provided is a composition for preventing, ameliorating, or treating inflammatory diseases, the composition including, as active ingredients, lactic acid bacteria-derived extracellular vesicles isolated from culture fluid of lactic acid bacteria; and a method for diagnosing atopic dermatitis. The composition including the lactic acid bacteria-derived extracellular vesicles as active ingredients is expected to be usefully used in development of drugs, cosmetics, or health functional food for preventing, ameliorating, or treating inflammatory diseases such as atopic dermatitis, chronic rhinitis, chronic rhinosinusitis, asthma, chronic obstructive pulmonary disease, sepsis, etc. Also, the composition will be usefully used for diagnosis of atopic dermatitis by measuring the distribution of lactic acid bacteria-derived extracellular vesicles in a urine or blood sample.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: September 10, 2019
    Assignee: MD HEALTHCARE INC.
    Inventors: Yoon-Keun Kim, Bok Yang Pyun, Minhye Kim, Jun-Pyo Choi
  • Patent number: 10336794
    Abstract: Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titres than OMVs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mltA gene. The invention also provides a bacterium, wherein the bacterium: (i) has a cell wall that includes peptidoglycan; and (ii) does not express a protein having the lytic transglycosylase activity MltA protein. The invention also provides compositions comprising vesicles that, during culture of bacteria of the invention, are released into the culture medium.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: July 2, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Jeannette Adu-Bobie, Mariagrazia Pizza, Nathalie Norais, Germano Ferrari, Guido Grandi
  • Patent number: 10335476
    Abstract: Certain embodiments are direct to a vaccine composition comprising an immunizing amount of an Ehrlichia sonicate, wherein the Ehrlichia sonicate elicits a protective physiologic response. In certain aspects the Ehrlichia is one or more of E. canis, E. chaffeensis, E. muris, E. ruminantium, E. ewingii, and E. ovis.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: July 2, 2019
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Sunil Thomas, David H. Walker
  • Patent number: 10324090
    Abstract: This disclosure provides a method for detecting infection of an animal by Mycobacterium bovis. The method generally includes obtaining a biological sample from a host animal at risk of being infected by Mycobacterium bovis and analyzing the sample for the presence or absence of at least one M. bovis polypeptide. In some embodiments, the method can further include analyzing the sample for the presence or absence of at least one M. bovis lipid. In some embodiments, the method can further include detecting at least one host polypeptide whose expression is greater in a host infected with M. bovis compared to expression in a host known to be uninfected with M bovis.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: June 18, 2019
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Srinand Sreevatsan, Elise Lamont
  • Patent number: 10232026
    Abstract: Disclosed is a vaccine which has a high therapeutic effect on mycoplasma infection and is highly safe. For the purpose of developing effective therapeutic methods for mycoplasma infection, mycoplasma-mimic particles which are effective as a vaccine for mycoplasma infection are provided, and also provided are bacterium-mimic particles including common bacteria. Bacterium-mimic particles such as mycoplasma-mimic particles can be provided by producing liposome particles in which a lipid antigen specific to a pathogenic bacterium such as mycoplasma is contained as a liposome-constituting lipid component. The administration of the mycoplasma-mimic particles enables the induction of a potent immunological activity in living bodies. The mycoplasma-mimic particles can be used as an excellent vaccine for the prevention or treatment of mycoplasma infection.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: March 19, 2019
    Assignees: NATIONAL INSTITUTE OF INFECTIOUS DISEASES, M BIO TECHNOLOGY INC.
    Inventors: Kazuhiro Matsuda, Koji Ichiyama, Sachie Matsuda, Yuko Sasaki, Yoshichika Arakawa, Ryo Harasawa, Yoshihiro Nishida, Norio Katayama, Yasuo Endo, Nobuo Nomura
  • Patent number: 10195259
    Abstract: Provided herein are compositions comprising substantially non-viable Gram-negative bacterial organisms that have a substantial reduction in endotoxin activity and/or pyrogenicity and methods for treating a cancer using the same. Also provided are methods for treating cancer provided herein, comprising administering to a mammal diagnosed with cancer, substantially non-viable Gram-negative bacteria having a substantial reduction in endotoxin activity and/or pyrogenicity, in an amount sufficient to inhibit growth or metastasis of the cancer. An additional method is provided comprising administering viable or non-viable Gram-negative bacterial organisms that have a genetic defect that results in a substantial loss of lipopolysaccharide within the outer membrane of the bacteria. Further provided are methods for reducing endotoxin activity and/or pyrogenicity in Gram-negative bacteria comprising treatment with polymyxin and glutaraldehyde.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: February 5, 2019
    Assignee: Decoy Biosystems, Inc.
    Inventor: Michael J. Newman
  • Patent number: 10188733
    Abstract: The present invention demonstrates that bisphosphonates have an intrinsic adjuvant activity and directly stimulate B cell antibody secretion. Accordingly, the present invention provides vaccines comprising a bisphosphonate, methods for stimulating an immune response, enhancing the immunogenicicty of an immunogen, and methods of treating an infection, an autoimmune disease, an allergy, and/or a cancer using the same.
    Type: Grant
    Filed: October 21, 2011
    Date of Patent: January 29, 2019
    Assignee: President and Fellows of Harvard College
    Inventors: Ulrich H. von Andrian, Matteo Iannacone, Elena Tonti, Elliott Ashley Moseman
  • Patent number: 10166186
    Abstract: The invention relates to a method for producing a nutritional and medicinal oral composition for veterinary use, comprising the following steps: a) providing cores of extruded products of complete feed, and b) coating the cores of extruded products of complete feed provided in step a) with at least one layer of a fatty material comprising at least one medicinal agent, said medicinal agent comprising (i) at least one pre-conditioned active substance in the form of a solution or a suspension of said active substance in an oily liquid, or (ii) at least one pre-conditioned active substance in the form of waxy granulates, at a temperature lower than 40° C.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: January 1, 2019
    Assignee: VIRBAC
    Inventors: Nicolas Brunel, Fanny Martins, Patricia Goisnard
  • Patent number: 10143736
    Abstract: This document relates to methods and materials for producing immune responses against polypeptides involved in antibiotic resistance. For example, vaccines against polypeptides involved in antibiotic resistance as well as methods for vaccinating mammals against polypeptides involved in antibiotic resistance are provided.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: December 4, 2018
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Michael A. Barry
  • Patent number: 10064930
    Abstract: The disclosure provides for immunogenic compositions against Pigeon Fever, and methods for their use and preparation. The immunogenic compositions, in alternate embodiments, also include other equine pathogens.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: September 4, 2018
    Inventors: Phillip Wayne Hayes, Kristina J. Hennessy
  • Patent number: 10054586
    Abstract: Mycobacterial-specific biomarkers and methods of using such biomarkers for diagnosis of mycobacterial infection in a mammal are disclosed.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: August 21, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Adel M. Talaat
  • Patent number: 10052371
    Abstract: Provided herein are compositions comprising substantially non-viable Gram-negative bacterial organisms that have a substantial reduction in endotoxin activity and/or pyrogenicity and methods for treating a cancer using the same. Also provided are methods for treating cancer provided herein, comprising administering to a mammal diagnosed with cancer, substantially non-viable Gram-negative bacteria having a substantial reduction in endotoxin activity and/or pyrogenicity, in an amount sufficient to inhibit growth or metastasis of the cancer. An additional method is provided comprising administering viable or non-viable Gram-negative bacterial organisms that have a genetic defect that results in a substantial loss of lipopolysaccharide within the outer membrane of the bacteria. Further provided are methods for reducing endotoxin activity and/or pyrogenicity in Gram-negative bacteria comprising treatment with polymyxin and glutaraldehyde.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: August 21, 2018
    Assignee: Decoy Biosystems, Inc.
    Inventor: Michael J. Newman
  • Patent number: 10023848
    Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides methods of inducing an immune response against a panton-valentine leukocidin (PVL)-expressing S. aureus, methods of preventing or treating S. aureus infections, and composition for preventing or treating S. aureus infections.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: July 17, 2018
    Assignee: INTEGRATED BIOTHERAPEUTICS, INC
    Inventors: Mohammad Javad Aman, Rajan Prasad Adhikari, Hatice Karauzum, Jawad Sarwar, Sergey Shulenin, Sathya Venkataramani, Kelly Lyn Warfield, Tam Luong Nguyen
  • Patent number: 10016493
    Abstract: Vaccines comprising TRAP polypeptides and Salmonella enteritidis vectors comprising TRAP polypeptides are provided. The vaccines may also include a CD154 polypeptide capable of binding to CD40. Also provided are methods of enhancing an immune response against Apicomplexan parasites and methods of reducing morbidity associated with infection with Apicomplexan parasites.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: July 10, 2018
    Assignees: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Walter Bottje, Billy Hargis, Luc Berghman, Young Min Kwon, Kimberly Cole, Mandy Cox, Sherryll Layton, Saeed El-Ashram, John Barta, Guillermo Tellez
  • Patent number: 10011662
    Abstract: The present invention relates to a novel process for purifying bacterial polysaccharide. It is an efficient and scalable process for removing impurities from Neisseria meningitidis serogroup C (Men-C) polysaccharide which is capable of being used as such in a derivatized form or linked to other molecules, for the preparation of vaccines, more particularly conjugate vaccines for N. meningitidis infection.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: July 3, 2018
    Assignee: MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD.
    Inventors: Davinder Gill, Manoj Kumar Chhikara, Sandeep Sharma, Sarmad Hanif, Neeraj Joshi
  • Patent number: 10004798
    Abstract: Provided herein are Salmonella enteritidis 13A strains and compositions comprising these strains. Also provided are methods of enhancing an immune response against Influenza A and methods of reducing morbidity associated with an Influenza A infection. Methods of enhancing an immune response to a vaccine vector by expressing a polypeptide of CD154 capable of binding CD40 are also disclosed. Methods of developing a bacterial vaccine vector are disclosed. Methods of generating scarless site-specific mutations in a bacterium are also disclosed.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: June 26, 2018
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventors: Walter Bottje, Billy Hargis, Luc Berghman, Young Min Kwon, Kimberly Cole, Mandy Cox, Sherryll Layton
  • Patent number: 9988679
    Abstract: Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: June 5, 2018
    Assignees: University of Washington, The UAB Research Foundation
    Inventors: Jens H. Gundlach, Michael Niederweis, Thomas Z. Butler, Mikhail Pavlenok, Mark A. Troll, Suja Sukumaran
  • Patent number: 9976149
    Abstract: A Listeria bacterium is disclosed which comprises a first mutation in the multidrug resistance transporter M (MdrM) gene which causes a decrease in interferon-? production in macrophages as compared to wild-type Listeria bacterium and a second mutation in the multidrug resistance transporter T (MdrT) gene which causes a decrease in interferon-? production in macrophages as compared to the wild-type Listeria bacterium.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: May 22, 2018
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Anat Afriat Herskovits, Millie Kaplan Zeevi
  • Patent number: 9957511
    Abstract: Various aspects and embodiments of the present disclosure are directed to methods and compositions for functionalizing endogenous bacteria in vivo. The methods include delivering to endogenous bacterial cells a recombinant bacteriophage or phagemid that is engineered to contain at least one genetic circuit.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: May 1, 2018
    Assignees: Massachusetts Institute of Technology, Trustees of Boston University
    Inventors: Timothy Kuan-Ta Lu, Robert James Citorik, James Collins, Russell-John Krom
  • Patent number: 9878024
    Abstract: Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically active Listeria that encodes an expressible antigen that is cross-reactive with the target antigen. In some examples, the immune response is a cellular immune response.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: January 30, 2018
    Assignee: ADURO BIOTECH, INC.
    Inventors: Thomas W. Dubensky, Jr., Dirk G. Brockstedt, Meredith Lai Ling Leong, Keith S. Bahjat
  • Patent number: 9855302
    Abstract: Provided herein are methods of treatment and/or prevention of cancer by manipulation of commensal microflora. In particular, the amount, identity, presence, and/or ratio of microflora (e.g., gut microflora) in a subject is manipulated to facilitate one or more co-treatments.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: January 2, 2018
    Assignee: The University of Chicago
    Inventors: Thomas F. Gajewski, Ayelet Sivan, Leticia Corrales
  • Patent number: 9796960
    Abstract: Provided is a method for preparing and using cell ghosts with active factors as a synergist of a lymphocyte in vitro culture. The method for preparing cell ghosts comprises: washing a cell to obtain a washed cell; and cleaving the washed cell to obtain cell ghosts, wherein the cell has cytokines capable of promoting the proliferation and differentiation of lymphocytes on their surface.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: October 24, 2017
    Inventor: Mingjie Zhang
  • Patent number: 9791440
    Abstract: The disclosure provides methods, compositions, and kits for enhanced detection of microbes in samples and monitoring of antimicrobial activity in a subject.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: October 17, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: Mark J. Cartwright, Nazita Gamini, Donald E. Ingber, Martin Rottman, Michael Super, Julie A. Tomolonis, Karen A. Sinclair
  • Patent number: 9771399
    Abstract: Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titers than OMVs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mltA gene. The invention also provides a bacterium, wherein the bacterium: (i) has a cell wall that includes peptidoglycan; and (ii) does not express a protein having the lytic transglycosylase activity MltA protein. The invention also provides compositions comprising vesicles that, during culture of bacteria of the invention, are released into the culture medium.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: September 26, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Jeannette Adu-Bobie, Mariagrazia Pizza, Nathalie Norais, Germano Ferrari, Guido Grandi
  • Patent number: 9764020
    Abstract: The invention provides proteins from Staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: September 19, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Vega Masignani, Marirosa Mora, Maria Scarselli
  • Patent number: 9757438
    Abstract: Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: September 12, 2017
    Assignee: MICROVAX, LLC
    Inventors: Yucheng Tang, Albert Deisseroth
  • Patent number: 9751915
    Abstract: The invention relates to mutant forms of Msp. The invention also relates to nucleic acid characterization using Msp.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: September 5, 2017
    Assignee: Oxford Nanopore Technologies Ltd.
    Inventors: James Clarke, Andrew John Heron, Lakmal Jayasinghe, Elizabeth Jayne Wallace, James White
  • Patent number: 9731005
    Abstract: A pharmaceutical composition for its use in the prophylactic treatment of a patient against an intracellular pathogen, said composition comprising a solid nanoparticle comprising a porous cationic-polysaccharide solid core, loaded with at least an anionic phospholipid, without said cationic-polysaccharide core being surrounded by any phospholipidic layer, and at least an antigen obtained from said pathogen.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: August 15, 2017
    Assignees: UNIVERSITE DE DROIT ET DE SANTE DE LILLE II, UNIVERSITE DE TOURS FRANCOIS RABELAIS, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE
    Inventors: Didier Betbeder, Isabelle Dimier-Poisson, Céline Ducournau
  • Patent number: 9708369
    Abstract: Disclosed are methods of altering metabolism of phosphate in a livestock via an antibody. The methods involve the development of an antibody against FGF-23 for the purpose of reducing phosphate excretion by an animal.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: July 18, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Mark E. Cook, Elizabeth A. Bobeck, Kimberly S. Burgess
  • Patent number: 9693578
    Abstract: The present invention relates to a method of producing a probiotic fruit beverage comprising a high viable count of acid-adapted probiotic bacteria, such as strains of Lactobacillus paracasei subsp. paracasei, and to probiotic fruit beverage obtainable by such method.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: July 4, 2017
    Assignee: Chr. Hansen A/S
    Inventors: Tina Hornbaek, Caroline Trebbien Gottlieb, Tina Malling Thorsen, Peter Sommer